Advances in glycosylation-mediated cancer-targeted drug delivery. Issue 5 (May 2018)

• Record Type: Journal Article
• Authors: Cai, Lulu; Gu, Zhipeng; Zhong, Jian; Wen, Di; Chen, Guojun; He, Lin; Wu, Jun; Gu, Zhen
• Is Part Of: Drug discovery today. Volume 23:Issue 5(2018)
• Page Start: 1126
• Page End: 1138
• Publication Date: 2018-05
• Subjects: Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2018.02.009
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: Aberrant tumor glycosylation has been used as a molecular target for cancer therapy. Advances in glycosylated strategies are allowing better targeted drug delivery. Glycosylated DDSs provide novel diagnostic, prognostic and therapeutic opportunities. Abstract : Targeted drug delivery for cancer therapy is expected to enhance therapeutic efficacy with minimized side effects, where the ligand-receptor recognition serves as a common targeting approach. Various ligands have been reported and carbohydrates, one of the crucial structures of tumor cell membranes, have been demonstrated effective for cell-selective binding. Hence, glycosylation-mediated cancer-targeted drug nanocarriers have received increasing attention in recent years. This review surveys a variety of glycosylated drug delivery systems as well as their applications for cancer therapy. Their challenges, opportunities, and future perspectives are also discussed in the end.